Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2019.04.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial.
Urol Oncol
October 2024
Division of Urology, Department of Surgical Oncology, University Health Network & University of Toronto, Toronto, Ontario, Canada; Division of Urology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Introduction: While observational studies suggest favorable associations between statin use and prostate cancer (CaP) outcomes, data from randomized-controlled trials remain inconclusive. Our study explores the relationship between statin use and survival outcomes in the context of the phase III ARAMIS study, a trial of darolutamide in the treatment of nonmetastatic castration-resistant prostate cancer.
Methods: We reviewed all 1,509 patients in the ARAMIS trial.
The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer.
Jpn J Clin Oncol
October 2024
Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Objective: The aim of this study was to compare prognostic outcomes of administering first- or second-generation androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer and to find prognostic indicators.
Methods: This retrospective study included 198 patients with non-metastatic castration-resistant prostate cancer from 14 institutions associated with Tokai Urologic Oncology Research Seminar. Forty-two patients were treated with combined androgen blockade using first-generation inhibitors (bicalutamide or flutamide), and 156 were treated with second-generation inhibitors (abiraterone/enzalutamide or apalutamide/darolutamide) after primary androgen deprivation therapy failure.
Prostate Cancer, Pathophysiology and Recent Developments in Management: A Narrative Review.
Curr Oncol Rep
November 2024
Department of Basic and Clinical Sciences, University of Nicosia Medical School, 21 Ilia Papakyriakou, 2414 Engomi, P.O. Box 24005, 1700, Nicosia, Cyprus.
Article Synopsis
- Prostate cancer is the second most common cancer in men, with various stages ranging from localized to metastatic disease, and treatment for advanced stages typically involves external beam radiotherapy and hormonal therapy for better prognosis.
- Current therapies for non-metastatic castration-resistant prostate cancer (M0 CRPCa) utilize androgen deprivation combined with new drugs, showing promising results in clinical trials for prolonging metastatic-free survival.
- New drug developments, including PARP inhibitors and Lutetium-177, along with ongoing clinical trials for treatments like cabozantinib and CAR T-cell therapy, aim to improve overall survival rates and slow disease progression in advanced prostate cancer cases.
Falls and fractures in men with prostate cancer taking second-generation androgen receptor antagonists: A retrospective chart review.
J Oncol Pharm Pract
October 2024
Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.
Introduction: Second-generation androgen receptor antagonists, including enzalutamide, apalutamide, and darolutamide, are commonly used to treat metastatic and non-metastatic prostate cancer. Although these medications are typically well-tolerated, falls were reported in 4.2-15.
View Article and Find Full Text PDFOptimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study.
Jpn J Clin Oncol
October 2024
Department of Urology, The Jikei University School of Medicine, 3-25-9, Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan.
Objective: We determined the optimal timing for initiating androgen receptor signaling inhibitor (ARSI) therapy in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and assessed its impact on oncological outcomes.
Materials And Methods: This retrospective study included 145 nmCRPC patients who received enzalutamide, apalutamide or darolutamide at the Jikei University Hospital or its affiliated institutions between May 2014 and November 2022. Patients were stratified based on prostate-specific antigen (PSA) doubling time (PSADT) at CRPC diagnosis and PSA levels at ARSI initiation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!